ReviewNature reviews. Rheumatology2020
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications.
Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04732663 (Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19), which is not on this map. Cited by 144 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19
Who cites it
144 citing papers in PubMed, 3 syntheses or guidelines pooled it, 239 citations in OpenAlex.
- Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.Endocrine · 2024Pooled it
- Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study.Thrombosis research · 2021Pooled it
- Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.Pharmacological reviews · 2021Pooled it
- Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.The Journal of clinical investigation · 2021Trial
- The Role of Immunosenescence and Inflammaging in the Susceptibility of Older Adults to SARS-CoV-2 Infection.Current pharmaceutical biotechnology · 2026Review
- Long-term alveolar-capillary diffusion impairments after severe SARS-CoV-2 pneumonia.Annals of medicine · 2025Article
- SARS-CoV-2 enhances complement-mediated endothelial injury via the suppression of membrane complement regulatory proteins.Emerging microbes & infections · 2025Article
- Article
- Jing-Yin-Gu-Biao formula protects mice from postinfluenzaFrontiers in immunology · 2025Article
- Analysis of Key Genes Related to Systemic Lupus Erythematosus and COVID-19.Combinatorial chemistry & high throughput screening · 2025Article
- Thrombotic microangiopathy with irreversible renal function in a CKD patient following COVID-19: case report.Frontiers in medicine · 2025Article
- Rapid prediction of acute thrombosis via nanoengineered immunosensors with unsupervised clustering for multiple circulating biomarkers.Science advances · 2024Article
- Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors.Cellular and molecular life sciences : CMLS · 2024Article
- Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: A Single-Center Experience.International journal of molecular sciences · 2024Article
- The past 25 years in paediatric rheumatology: insights from monogenic diseases.Nature reviews. Rheumatology · 2024Review
- Impaired instructive and protective barrier functions of the endothelial cell glycocalyx pericellular matrix is impacted in COVID-19 disease.Journal of cellular and molecular medicine · 2024Review
- Catastrophic Antiphospholipid Syndrome.International journal of molecular sciences · 2024Review
- Thyroid Autoimmunity and SARS-CoV-2 Infection.Journal of clinical medicine · 2023Review
- Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19.Cell stem cell · 2023Article
- Clinicopathologic Analysis of COVID-19 Associated Thrombi in the Setting of Large Vessel Occlusion: A Prospective Case-Control Study.Stroke (Hoboken, N.J.) · 2023Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Reports of widespread thromboses and disseminated intravascular coagulation (DIC) in patients with coronavirus disease 19 (COVID-19) have been rapidly increasing in number. Key features of this disorder include a lack of bleeding risk, only mildly low platelet counts, elevated plasma fibrinogen levels, and detection of both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and complement components in regions of thrombotic microangiopathy (TMA). This disorder is not typical DIC. Rather, it might be more similar to complement-mediated TMA syndromes, which are well known to rheumatologists who care for patients with severe systemic lupus erythematosus or catastrophic antiphospholipid syndrome. This perspective has critical implications for treatment. Anticoagulation and antiviral agents are standard treatments for DIC but are gravely insufficient for any of the TMA disorders that involve disorders of complement. Mediators of TMA syndromes overlap with those released in cytokine storm, suggesting close connections between ineffective immune responses to SARS-CoV-2, severe pneumonia and life-threatening microangiopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.